[go: up one dir, main page]

BRPI0406800A - Peptìdio dimerizado - Google Patents

Peptìdio dimerizado

Info

Publication number
BRPI0406800A
BRPI0406800A BR0406800-9A BRPI0406800A BRPI0406800A BR PI0406800 A BRPI0406800 A BR PI0406800A BR PI0406800 A BRPI0406800 A BR PI0406800A BR PI0406800 A BRPI0406800 A BR PI0406800A
Authority
BR
Brazil
Prior art keywords
peptide
dimerized
tumor antigen
dimerized peptide
peptidia
Prior art date
Application number
BR0406800-9A
Other languages
English (en)
Inventor
Haruo Sugiyama
Hideo Takasu
Fumio Samizo
Original Assignee
Haruo Sugiyama
Chugai Pharmaceutical Co Ltd
Sumitomo Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haruo Sugiyama, Chugai Pharmaceutical Co Ltd, Sumitomo Pharma filed Critical Haruo Sugiyama
Publication of BRPI0406800A publication Critical patent/BRPI0406800A/pt
Publication of BRPI0406800A8 publication Critical patent/BRPI0406800A8/pt
Publication of BRPI0406800B1 publication Critical patent/BRPI0406800B1/pt
Publication of BRPI0406800B8 publication Critical patent/BRPI0406800B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"PEPTìDIO DIMERIZADO". A presente invenção refere-se a um novo peptídio antígeno de tumor e a vacina para câncer do mesmo, de modo específico um dímero de peptídio, no qual dois monómeros de peptídio que consistem em 7 a 30 aminoácidos que incluem, pelo menos um resíduo de cisteína e sendo capazes de produzir um peptídio antígeno de tumor estão ligados um com o outro através de uma ligação de dissulfeto.
BRPI0406800A 2003-01-15 2004-01-15 "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso BRPI0406800B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003-007122 2003-01-15
JP2003007122 2003-01-15
PCT/JP2004/000254 WO2004063217A1 (ja) 2003-01-15 2004-01-15 二量体化ペプチド

Publications (4)

Publication Number Publication Date
BRPI0406800A true BRPI0406800A (pt) 2006-01-17
BRPI0406800A8 BRPI0406800A8 (pt) 2016-11-01
BRPI0406800B1 BRPI0406800B1 (pt) 2020-08-11
BRPI0406800B8 BRPI0406800B8 (pt) 2021-05-25

Family

ID=32709100

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0406800A BRPI0406800B8 (pt) 2003-01-15 2004-01-15 "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso

Country Status (12)

Country Link
US (2) US20060217297A1 (pt)
EP (2) EP1584627B1 (pt)
JP (2) JP4498274B2 (pt)
KR (2) KR20120054644A (pt)
CN (2) CN1756763B (pt)
AT (1) ATE444969T1 (pt)
AU (1) AU2004204031B2 (pt)
BR (1) BRPI0406800B8 (pt)
CA (1) CA2513701C (pt)
DE (1) DE602004023476D1 (pt)
ES (1) ES2332590T3 (pt)
WO (1) WO2004063217A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1103564E (pt) * 1998-07-31 2009-03-13 Int Inst Cancer Immunology Inc Antigénios de cancro com base no produto do gene supressor de tumor wt1
EP1371664B1 (en) * 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
CN1511040A (zh) * 2001-05-25 2004-07-07 ����˹���ѷ��ѧ 作为多种治疗模式基础的蛋白质的选择性剪接形式
US7342092B2 (en) * 2002-09-12 2008-03-11 International Institute Of Cancer Immunology, Inc. Cancer antigen peptide formulations
CN100513563C (zh) 2003-11-05 2009-07-15 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
ATE462003T1 (de) * 2004-03-31 2010-04-15 Int Inst Cancer Immunology Inc Aus wt1 stammende krebsantigenpeptide
CN103169958A (zh) * 2005-02-04 2013-06-26 萨瓦克公司 存活蛋白肽疫苗
CA2631292C (en) 2005-11-30 2014-05-06 International Institute Of Cancer Immunology, Inc. Derivatised wt1 cancer antigen peptides and their use
SI1988163T1 (sl) * 2006-02-22 2012-09-28 Int Inst Cancer Immunology Inc HLA-A*3303-omejen WT1 peptid in farmacevtski sestavek, ki ga vsebuje
ES2333374T3 (es) * 2006-02-23 2010-02-19 FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH Peptidos y derivados de peptidos, la produccion de los mismos asi como su uso para preparar una composicion farmaceutica terapeutica y/o preventivamente activa.
CA2670658A1 (en) * 2006-12-28 2008-07-10 International Institute Of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
CA2677075C (en) 2007-02-27 2018-07-10 International Institute Of Cancer Immunology, Inc. Method for activation of helper t cell and composition for use in the method
MX2010002264A (es) * 2007-08-30 2010-08-02 Curedm Inc Composiciones y métodos para utilizar péptidos proislet y sus analogos.
KR20140009168A (ko) 2010-10-05 2014-01-22 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 헬퍼 ｔ 세포의 활성화 방법
NZ611176A (en) * 2010-12-02 2015-07-31 Bionor Immuno As Peptide scaffold design
CN103270047A (zh) * 2010-12-23 2013-08-28 因特塞尔奥地利股份公司 Oprf/i剂及其在住院患者和其他患者中的用途
CA2821995C (en) 2011-01-06 2019-02-12 Bionor Immuno As Monomeric and multimeric peptides immunogenic against hiv
WO2012105224A1 (ja) * 2011-01-31 2012-08-09 オリンパス株式会社 ワクチン・アジュバント
ES2655031T3 (es) 2012-07-02 2018-02-16 Sumitomo Dainippon Pharma Co., Ltd. Preparación transdérmica de péptido antigénico del cáncer
JP6530192B2 (ja) 2012-12-17 2019-06-12 大塚製薬株式会社 ヘルパーｔ細胞の活性化方法
CA2905588C (en) 2013-03-12 2018-11-06 Sumitomo Dainippon Pharma Co., Ltd. Liquid aqueous composition
EP2980097A4 (en) * 2013-03-29 2017-03-08 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of erap1
CA2907782C (en) * 2013-03-29 2021-01-05 Sumitomo Dainippon Pharma Co., Ltd. Wt1 antigen peptide conjugate vaccine
JP2016539922A (ja) 2013-10-17 2016-12-22 ソウル ナショナル ユニバーシティ アールアンドディービー ファウンデーション 細胞透過性αヘリックスペプチド多量体、これの製造方法およびその用途
EP3199175B1 (en) * 2014-09-27 2022-03-23 Sumitomo Dainippon Pharma Co., Ltd. Pharmaceutical composition for injection
JP6671141B2 (ja) * 2014-10-21 2020-03-25 大日本住友製薬株式会社 懸濁液剤
ES2993462T3 (en) * 2015-05-20 2024-12-30 Sumitomo Pharma Co Ltd Combination of wt1 antigen peptide, immunomodulator and wt1 helper peptide
CA2992419C (en) * 2015-07-14 2023-08-15 Yeda Research And Development Co. Ltd. Peptide combinations for use in the diagnosis of schizophrenia
JP7209963B2 (ja) 2016-11-30 2023-01-23 住友ファーマ株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
CN111741972A (zh) * 2017-12-27 2020-10-02 大日本住友制药株式会社 Wt1衍生肽的缀合物和包含其的组合物
US12233130B2 (en) 2022-12-22 2025-02-25 Defence Therapeutics Inc. Covalently-modified steroid acid-peptides having enhanced stability and/or biological activity

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE332710T1 (de) * 1995-06-01 2006-08-15 Kishimoto Tadamitsu Wachstumsinhibitor gegen leukämische zellen, der antisense-oligonukleotidderivate gegen das wilms- tumorgen enthält
JP3060287B2 (ja) 1995-10-09 2000-07-10 参天製薬株式会社 アパファントを主薬とする水性点眼剤
PT1103564E (pt) * 1998-07-31 2009-03-13 Int Inst Cancer Immunology Inc Antigénios de cancro com base no produto do gene supressor de tumor wt1
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
KR100752065B1 (ko) * 1998-09-30 2007-08-28 코릭사 코포레이션 Ｗｔ1 특이적 면역요법용 조성물 및 방법
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
WO2002047474A1 (en) 2000-12-13 2002-06-20 Sumitomo Pharmaceuticals Company, Limited Transgenic animal expressing hla-a24 and utilization thereof
EP1371664B1 (en) * 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
WO2003028758A1 (en) * 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
EP1447091A4 (en) * 2001-09-28 2008-02-13 Institute Of Can International NEW METHOD FOR INDUCTION OF ANTIGEN SPECIFIC T CELLS
EP1536009B1 (en) * 2002-06-12 2010-04-28 International Institute of Cancer Immunology, Inc. Hla-a24-restricted cancer antigen peptide
CN100513563C (zh) 2003-11-05 2009-07-15 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
ATE462003T1 (de) 2004-03-31 2010-04-15 Int Inst Cancer Immunology Inc Aus wt1 stammende krebsantigenpeptide

Also Published As

Publication number Publication date
ATE444969T1 (de) 2009-10-15
JPWO2004063217A1 (ja) 2006-06-01
KR20050098863A (ko) 2005-10-12
CN101851275A (zh) 2010-10-06
DE602004023476D1 (de) 2009-11-19
AU2004204031A1 (en) 2004-07-29
CA2513701C (en) 2013-06-18
EP2154145B1 (en) 2013-04-24
BRPI0406800B8 (pt) 2021-05-25
WO2004063217A1 (ja) 2004-07-29
CN1756763B (zh) 2010-05-26
EP1584627A1 (en) 2005-10-12
JP4926231B2 (ja) 2012-05-09
US8242084B2 (en) 2012-08-14
US20100292164A1 (en) 2010-11-18
HK1081975A1 (en) 2006-05-26
BRPI0406800B1 (pt) 2020-08-11
EP1584627A4 (en) 2006-03-15
EP1584627B1 (en) 2009-10-07
ES2332590T3 (es) 2010-02-09
BRPI0406800A8 (pt) 2016-11-01
AU2004204031B2 (en) 2010-03-04
JP2010047603A (ja) 2010-03-04
EP2154145A3 (en) 2010-05-19
US20060217297A1 (en) 2006-09-28
CN1756763A (zh) 2006-04-05
EP2154145A2 (en) 2010-02-17
CA2513701A1 (en) 2004-07-29
JP4498274B2 (ja) 2010-07-07
HK1141539A1 (en) 2010-11-12
KR101399678B1 (ko) 2014-05-27
KR20120054644A (ko) 2012-05-30

Similar Documents

Publication Publication Date Title
BRPI0406800A (pt) Peptìdio dimerizado
BR0211623A (pt) Agentes de contraste alvos multiméricos com base em peptìdeo
BRPI0414497A (pt) análogos de talidomida
CY1118037T1 (el) Αντισωματα εναντι του αβητα και h χρηση τους
BR0305074A (pt) Composições cosméticas com alta afinidade
MX2009007008A (es) Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo.
BR0309868A (pt) Conjugados de derivados de caliqueamicina - veìculo
CY1113850T1 (el) Νεα παραγωγα ινσουλινης
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
CR8444A (es) Immunogenic peptide carrier conjugates and methods of producing same
BR0316092A (pt) Anticoprpos de domìnio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos
DK1423419T3 (da) Hybrid- og tandemekspression af Neisseria-proteiner
AR033978A1 (es) Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas
ATE536188T1 (de) Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
PE20081634A1 (es) Fab ab pegilado
GT200300072AA (es) Aminoacidos con afinidad por la proteina alfa2delta (solicitud fraccionaria
BR0008916A (pt) Composiçao nutricional projetada para maturação gastrointestinal especìfica em mamìferos prematuros
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
DK1873166T3 (da) Forbedrede sgp 130Fc-dimerer
UY30984A1 (es) Proteinas de fusion de formula m-a para degradar péptidos beta amiloides, composiciones en base a ella, preparacion y aplicaciones.
BRPI0505302A (pt) processo de toner
BR0315864A (pt) Composições e processos para a modificação efeitos tóxicos de compostos proteináceos
PE20050962A1 (es) Anticuerpos completamente humanos contra 4-1bb humano
ATE495247T1 (de) Chromoprotein und fluoroproteine

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: CHUGAI SEIYAKU KABUSHIKI KAISHA (CHUGAI PHARMACEUT

B25A Requested transfer of rights approved

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/01/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) ; SUMITOMO PHARMA CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) ; SUMITOMO PHARMA CO., LTD. (JP)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2809 DE 05-11-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.